https://www.selleckchem.com/pr....oducts/selonsertib-g
Previous studies have demonstrated that programmed cell death-ligand 1 (PD-L1) serves as biomarker for poor prognosis and survival in advanced-stage non-small cell lung cancer (NSCLC) patients. However, the merit ofPD-L1 expression to predict the prognosis of early stage NSCLC patients who underwent complete resection remains controversial. In the present study, we performed a meta-analysis to investigate the relationship betweenPD-L1expression and prognosis in patients with early stage resected NSCLC. Electronic databases,
Like
Comment
Share
